Allen Salem, MD
Pulmonary Disease · Idaho Falls, IDNPI 1992797088
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by United Therapeutics Corporation at 48.4% of the total. Reporting peaked in 2019 at $17,972 and has fallen 95.1% since, to $874 in 2025. Among pulmonary disease clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 413 payments — averaging $105.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$21K
- Boehringer Ingelheim$8K
- Mylan Specialty L.p.$7K
- Inspire Medical Systems, Inc.$2K
- Bayer$2K
- GSK$905
- plus $2K from 20 others
What the payments were for
- Consulting fees$7,33017%
- Speaking & faculty fees$25,62059%
- Travel & lodging$3,6208%
- Food & beverage$6,84816%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 86 | $21,100 |
| Boehringer Ingelheim | 29 | $8,285 |
| Mylan Specialty L.p. | 28 | $7,279 |
| Inspire Medical Systems, Inc. | 31 | $2,035 |
| Bayer | 16 | $1,610 |
| GSK | 86 | $905 |
| Grifols USA, LLC | 16 | $318 |
| Sanofi | 17 | $307 |
| AstraZeneca | 20 | $301 |
| Insmed, Inc. | 10 | $254 |
| Sunovion Pharmaceuticals Inc. | 24 | $239 |
| Harmony Biosciences LLC | 9 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $127 |
| Philips North America LLC | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 6 | $103 |
| Baxter Healthcare | 3 | $69 |
| Advanced Respiratory, Inc | 4 | $61 |
| Merck | 3 | $60 |
| Jazz Pharmaceuticals Inc. | 2 | $52 |
| CSL Behring | 3 | $47 |
| AbbVie(2 entities) | 3 | $47 |
| Gilead | 2 | $32 |
| Resmed Corp | 1 | $30 |
| Lilly USA, LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,618 in reported general payments places this provider in the 95th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $300,843 |
| AdempasRiociguat | 21 | $287,085 |
| Orenitram ErTreprostinil Diolamine | 11 | $110,489 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $23,688 |
| Pirfenidone | 22 | $13,128 |
| EliquisApixaban | 16 | $9,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,251 |
| Qvar RedihalerBeclomethasone Dipropionate | 16 | $5,778 |
| Theo-24Theophylline Anhydrous | 15 | $2,783 |
| Theophylline ErTheophylline Anhydrous | 25 | $1,795 |
| Ipratropium Bromide | 42 | $1,130 |
| Mycophenolate Mofetil | 15 | $710 |
| Prednisone | 79 | $519 |
| Dexamethasone | 21 | $383 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $8,285 | $324,53158 claims |
| BayerAdempas | $1,610 | $287,08521 claims |
| GSKTrelegy Ellipta | $905 | $7,25112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Idaho Falls
- Jordan CormierIdaho Falls$9K
- Todd HoopmanCoeur D Alene$76K
- Mark RasmusBoise$44K
- Shawn FrenchTwin Falls$26K
- Karen MillerMeridian$12K
- Wesley PidcockNampa$12K
- Norman EastBoise$11K
- Oleg KouskovMeridian$8K
- Derek LindermanBoise$7K
- Gregory BallTwin Falls$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.